Bcl-2-modifying factor (BMF)

Bcl-2-modifying factor (BMF) is a pro-apoptotic, BH3-only protein of the BCL2 family, acting as a sentinel for cellular stress. It is sequestered to the cytoskeleton via binding dynein light chain-2 (DYNLL2), released and translocated to mitochondria following stress, where it binds and neutralizes anti-apoptotic BCL2 proteins leading to activation of the intrinsic apoptotic pathway[1][2][3][4]. BMF is regulated by transcription factors, histone deacetylases, microRNAs, and post-translational modifications, notably phosphorylation by JNK on serine-74, which increases its apoptotic function[2][3]. Loss of BMF confers resistance to programmed cell death, promotes lymphocyte hyperplasia, and increases susceptibility to certain cancers and developmental defects[2][3]. BMF is induced by stress signals such as loss of matrix attachment (anoikis), cytokines, and various anti-cancer agents, implicating it in both physiological development and disease states, especially cancer[2][3].

Other names

BMFBcl2 modifying factorbcl-2-modifying factorFLJ00065

Induction of apoptosis through disruption of anti-apoptotic BCL2 proteins, promoting mitochondrial membrane permeabilization via Bax/Bak activation. Release from cytoskeleton under stress and subsequent mitochondrial targeting. JNK-mediated phosphorylation to increase apoptotic activity.